Xenon Pharmaceuticals Files 8-K on Shareholder Votes & Exhibits
Ticker: XENE · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
Related Tickers: XENE
TL;DR
Xenon Pharma filed an 8-K for shareholder votes and financials. Standard stuff.
AI Summary
On June 4, 2025, Xenon Pharmaceuticals Inc. filed an 8-K report to disclose matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details on the votes or financial figures within this summary.
Why It Matters
This filing indicates that Xenon Pharmaceuticals Inc. is engaging in corporate actions requiring shareholder approval and is providing necessary financial documentation, which are standard but important disclosures for investors.
Risk Assessment
Risk Level: low — This is a routine filing for corporate actions and financial disclosures, not indicating any immediate material adverse events.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- June 4, 2025 (date) — Date of earliest event reported
- 200-3650 Gilmore Way Burnaby, British Columbia, Canada V5G 4W8 (address) — Principal Executive Offices
- ( 604 ) 484-3300 (phone_number) — Registrant's Telephone Number
FAQ
What specific matters were submitted to a vote of Xenon Pharmaceuticals Inc. security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the summary information of this 8-K.
What financial statements and exhibits are being filed with this 8-K?
The filing states that financial statements and exhibits are being filed, but the specific content of these documents is not detailed in the provided summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 4, 2025.
What is the principal executive office address for Xenon Pharmaceuticals Inc.?
The principal executive office address for Xenon Pharmaceuticals Inc. is 200-3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
What is the IRS Employer Identification Number for Xenon Pharmaceuticals Inc.?
The IRS Employer Identification Number for Xenon Pharmaceuticals Inc. is 98-0661854.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Xenon Pharmaceuticals Inc. (XENE).